Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Green Plus JSCHSTC:GPC 32 Debt-to-EBITDA is 0.00 as of . 20. GuruFocus rates HSTC:GPC with a GF Score™ of 32/100. The stock has 1 warning sign investors should review. Among 690 Drug Manufacturers companies, Green Plus JSC ranks worse than 144927.39% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Green Plus JSC's Debt-to-EBITDA or its related term are showing as below:
HSTC:GPC's Debt-to-EBITDA is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.67 * Ranked among companies with meaningful Debt-to-EBITDA only.
Green Plus JSC (HSTC:GPC) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Green Plus JSC Debt-to-EBITDA Related Terms
Green Plus JSC Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Green Plus JSC's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Green Plus JSC Debt-to-EBITDA Chart
Green Plus JSC Annual Data
Trend
Debt-to-EBITDA
Green Plus JSC Semi-Annual Data
Debt-to-EBITDA
HSTC:GPC vs ZTS, UTHR, VTRS: Debt-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Green Plus JSC's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Green Plus JSC Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Green Plus JSC's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Green Plus JSC's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is one times the quarterly (. 20) EBITDA data.
Green Plus JSC (HSTC:GPC) has a Debt-to-EBITDA of 0.00 as of . 20. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Green Plus JSC. According to the industry distribution chart, Green Plus JSC ranks #999999 out of 690 companies in the Drug Manufacturers industry.
Is Green Plus JSC's Debt-to-EBITDA too high?
Green Plus JSC's current Debt-to-EBITDA is 0.00. Based on the distribution chart, Green Plus JSC ranks #999999 out of 690 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Green Plus JSC has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Green Plus JSC's Debt-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Green Plus JSC ranks #999999 out of 690 companies for Debt-to-EBITDA. This places Green Plus JSC in the lower half of its industry. The industry median Debt-to-EBITDA is 1.67. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.67, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Green Plus JSC. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Green Plus JSC's current Debt-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Green Plus JSC stock overvalued right now?
Green Plus JSC (HSTC:GPC) has a current Debt-to-EBITDA of 0.00. The current Debt-to-EBITDA is 0.00. Green Plus JSC's overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Green Plus JSC (HSTC:GPC), the current Debt-to-EBITDA is 0.00 as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Green Plus JSC is engaged in manufacturing and distributing pharmaceutical and herbal products. The Company was established with the mission of improving public health by providing health food products of natural origin, high quality, safe and effective. Company has also chosen to cooperate with a reputable international partner from Japan so that Vietnamese people can use high-quality functional food products at reasonable prices. In addition, Green+ constantly invests in research, product development and service improvement with a team of dedicated and experienced experts to bring truly different values.
32GF Score
Get the complete analysis for HSTC:GPC
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HSTC:GPC has been successfully added to your 
